Related Experiment Video
Updated: Sep 17, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
Thrombin dynamics and clinical events in cirrhosis: low prothrombin conversion predicts bleeding risk
Ruth Anne Laura Willems1,2,3,4, Alberto Zanetto5,6, Elena Campello7,8
1Department of Functional Coagulation, Synapse Research Institute, Maastricht, Netherlands.
Abstract:
Pro- and anti-coagulant factors are significantly altered in liver cirrhosis resulting in an increased bleeding and thrombosis risk. The thrombin generation (TG) test often seems unaltered in cirrhosis, indicating that a new hemostatic balance is reached. TG is determined by prothrombin conversion and thrombin inactivation. These processes can be quantified using the computational thrombin dynamics (TD) add-on analysis for the TG test. We studied TD parameters in cirrhosis to explore its predictive potential for bleeding and thrombosis. In the current study, 32 CP-A, 22 CP-B and 41 CP-C cirrhosis patients and 20 healthy controls were enrolled. Cirrhosis was predominantly alcohol-related (52%), while viral and metabolic etiologies accounted for 34% and 14% of cases, respectively. Patients receiving anticoagulant therapy were excluded. TG was measured using PPP Reagent Low in the presence and absence of thrombomodulin. TG peak height and velocity index were higher in patients than controls (+20%,p = 0.039 and +70%,p = 0.002), and time-to-peak was shorter (-18%,p < 0.0001). TD parameters were obtained computationally based on TG and coagulation factor data. The amount of prothrombin converted (PCtot) was significantly reduced in patients (-43%,p < 0.0001), and the magnitude of the reduction was associated with disease severity. The maximum rate of prothrombin conversion (PCmax) showed a trend towards higher levels in CP-A patients. On the anticoagulant slide, the thrombin decay capacity (TDC) was significantly lower in patients (-44%,p < 0.0001), indicating a newly developed balance between pro- and anticoagulant processes that result in a slightly procoagulant TG phenotype. Four patients experienced bleeding and seven experienced thrombosis during follow-up (median = 499 days; CI: 478-524 days). Low maximum prothrombin conversion rates (PCmax) were associated with an increased hazard of bleeding. Patients in the lowest 20% of PCmax had a HR of 12.9 (95% CI 1.34-124.31, p = 0.027) for bleeding. Low thrombin-α2Macroglobulin (T-α2M) complex formation was significantly associated with thrombosis during follow-up. Patients in the lowest quintile of T-α2M had a HR of 6.6 (95% CI 1.47-29.9, p = 0.014) for thrombosis. We conclude that reduced prothrombin conversion and thrombin inactivation result in rebalanced TG in cirrhosis patients. Our results demonstrate the potential clinical usefulness of TD parameters for the stratification of bleeding and thrombotic risk in cirrhosis patients.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis III: Interprofessional Care
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Clot Retraction and Fibrinolysis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
